Find information on thousands of medical conditions and prescription drugs.

Fraser syndrome

An autosomal recessive genetic disease, characterized by developmental defects including underdevelopment of the eyes (crytophthalmos) and the genitals (micropenis, cryptorchidism or clitoromegaly). Congenital malformations of the nose, ears,larynx, and renal system as well as mental retardation are manifest occasionally. The Fraser syndrom is also known as: Meyer-Schwickerath's syndrome, Fraser-Fran├žois syndrome, or Ullrich-Feichtiger syndrome.

The genetic background of this disease has been linked to a gene called FRAS1, which seems to be involved in skin epithelial morphogenesis during early development.

Fabry's disease
Factor V Leiden mutation
Factor VIII deficiency
Fallot tetralogy
Familial adenomatous...
Familial Mediterranean fever
Familial periodic paralysis
Familial polyposis
Fanconi syndrome
Fanconi's anemia
Farber's disease
Fatal familial insomnia
Fatty liver
Febrile seizure
Fibrodysplasia ossificans...
Fibrous dysplasia
Fissured tongue
Fitz-Hugh-Curtis syndrome
Flesh eating bacteria
Focal dystonia
Foix-Alajouanine syndrome
Follicular lymphoma
Fountain syndrome
Fragile X syndrome
Fraser syndrome
FRAXA syndrome
Friedreich's ataxia
Frontotemporal dementia
Fructose intolerance


[List your site here Free!]

Herbs for mental illness: effectiveness and interaction with conventional medicines: some herbs do work as claimed; all have the potential for downside
From Journal of Family Practice, 9/1/05 by Monica Vermani

Practice recommendations

* Many of your patients may be self-treating with herbal preparations. Ask candidly about this possibility, and become familiar with the increasing evidence on efficacy and safety of alternative treatments

* A large meta-analysis and a Cochrane Review both suggest St. John's Wort (A) is as effective as conventional antidepressants and more effective than placebo for mild to moderate depression. With patients taking St. John's Wort and a conventional antidepressant, remain alert for a potentiating effect, "serotonin syndrome." Use with caution if the patient must also receive anticoagulants, oral contraceptives, or antiviral agents.

* The efficacy and safety of ginseng (B, in terms of psychological well-being) and evening primrose (C) for depression are not well established.

* Kava-kava (A, for short-term treatment for anxiety treatment) has well-known anxiolytic properties, but its potential adverse effects, particularly liver toxicity, dramatically reduce its usefulness. Valerian, though commonly used for anxiety (C, for insomnia and anxiety), is not well supported by good data.

* Ginkgo has shown promise in improving cognitive function in dementia, and its side effects are few and uncommon (A, for cognitive function in dementia). Monitor carefully if there is concomitant anticoagulant therapy.

Based on epidemiologic estimates, it may be that 20% to 30% of your patient population is using alternative/complementary medicines. Twenty percent of adults who take prescription medicine also rely on herbal products, (2) and patients who use herbal products the most are those with chronic conditions. (3)

Included in this group are persons with mental health problems, who, compared with the general population, report a much greater use of alternative treatments, including herbal and homeopathic remedies. (4) These remedies, when used to treat psychiatric symptoms, may produce changes in mood, thinking, or behavior, and they may interact with a number of conventional medications. (3)

Largely uncharted territory. With the exception of St. John's Wort for depression and ginkgo for dementia, minimal evidence is currently available to recommend the use of herbal medicines as the primary treatment for mental illness. Although some herbs have been found to be effective at specific doses for specific conditions, there is no evidence to show their superiority to conventional drug treatments, nor has their safety been established for use during pregnancy and lactation. (8)

Helping patients navigate. Nevertheless, our patients are increasingly turning to alternative therapies, and it is therefore critical that we clinicians avail ourselves of current knowledge and that investigators pursue intensive clinical research to establish safety (TABLE 1) and efficacy. Additionally, greater understanding of the biochemical and pharmacological effects of these herbs may uncover novel treatments or yield fresh insights into basic disease mechanisms. (9)

The herbal remedies discussed in this article are those commonly used for psychiatric conditions. Their effectiveness and potential for adverse side effects and interactions are assessed.

* Depression

St. John's wort

St. John's Wort (Hypericum perforatum L) is a popular herbal treatment readily used by the public in various forms, such as tablets and teas. Efficacy of hypericum--one of the hypothesized active ingredients in St. John's Wort--in the treatment of depression was reported in the texts of the ancient Greek physicians Hippocrates, Pliny, and Galen, and it continued to be cited throughout the Classical, Renaissance, and Victorian eras. Its contemporary usage as an antidepressant has been supported by more rigorous evidence than any other herbal remedy. (9)

Efficacy. Evidence of efficacy in mild to moderate depression has been reported in a meta-analysis of 23 randomized trials with a total of 1757 outpatients, in which extracts of St. John's Wort alone (20 of 23 trials) or in combination with other herbs (3 of 23) were tested against placebo (15 trials) or antidepressant drugs (8 trials). (10) St. John's Wort was reported to be clearly superior to placebo and comparable with conventional drug treatment, with lower side-effect and dropout rates. Similarly, a recent Cochrane Review of 27 trials and 2291 patients concluded that St. John's Wort was more effective than placebo in treating mild to moderately severe depression; however, there was inadequate evidence to determine whether the herb was as effective as traditional antidepressants. (11)

The superiority of hypericum to placebo has been called into question, however, by a large-scale, multicenter, double-blind case report tabulation. The study, conducted with 200 patients across 11 academic medical centers in the United States, found no evidence that St. John's Wort was more efficacious than placebo. (12) Another such trial also concluded that St. John's Wort was not an effective treatment for major depression. In addition, the herb was found to be no different than sertraline, which was also indistinguishable from the placebo, further confusing the issue. (13) Strength of recommendation (SOR) is level A for the evidence in support of St. John's Wort as an antidepressant.

Mechanisms of action. The mechanisms for the antidepressant effects of St. John's Wort are not fully understood, although monoamine oxidase (MAO) inhibition, inhibition of serotonin receptor expression, serotonin reuptake inhibition, and reduction of cytokine expression have all been suggested as means of its activity. (9)

Herb-drug interactions. Evidence suggests St. John's Wort contains both inhibitory and inducing constituents for the cytochrome P-450 (CYP) system, resulting in both inhibition and induction on the CYP system. (14) Consequently, it's difficult to predict which drugs St. John's Wort will interact with in a significant way. (15) Best estimates of its activity suggest it has minimal short-term activity; when used for a longer period, it will inhibit the CytP450-3A4, 2C19, and 2D6 systems (TABLE 2). Therefore, St. John's Wort may alter the blood levels of such medications as anticoagulants, (16) oral contraceptives, (18) and antiviral agents, (19) possibly resulting in serious consequences. (16,17) Exercise caution when initiating treatment for patients already taking St. John's Wort.

The potential of St. John's Wort to interact with standard prescribed antidepressants, possibly to produce a "serotonin syndrome," is also a concern. Gordon (20) reported a case in which a woman taking St. John's Wort became groggy, weak, and lethargic shortly after taking a single 20mg dose of paroxetine. This patient had tolerated St. John's Wort and paroxetine separately, suggesting a drug-herb interaction. (3) St. John's Wort has also been implicated in reducing blood levels of digoxin when the two are taken together, (21) and 1 study documented that 8% of psychiatrists treating patients who had used St. John's Wort reported drug interactions between the herb and another agent. (22)

Adverse effects. In general, fewer adverse effects are seen with hypericum than with conventional antidepressants but they may include photodermatitis, delayed hypersensitivity, gastrointestinal tract upset, dizziness, dry mouth, sedation, restlessness, and constipation. Use of St. John's Wort is contraindicated during pregnancy and lactation, for patients who experience intense exposure to strong sunlight, and for patients with a pheochromocytoma. (23)

There are several anecdotal reports of mania or hypomania associated with the herb. For example, O'Breasail and Argouarch (24) reported 2 cases of persons with no history of bipolar disorder who developed hypomanic episodes after taking St. John's Wort. Likewise, Moses and Mallinger (25) reported 3 cases of possible mania induction associated with the herb.


This herb is derived from the root of Panax ginseng and has been used as a cure-all in Eastern folk medicine for thousands of years. (26) Today, both Chinese ginseng (P ginseng CA Meyer) and North American ginseng (P quinquefolius L) are associated with the treatment of mood and anxiety disorders and are used to reduce stress and fatigue and to improve endurance.

Efficacy. A systematic review of 16 double-blind randomized controlled trials found that ginseng did not improve cognitive function or psychomotor and physical performance. (27) Another review reported conflicting results from several studies. (28) For example, 1 double-blind randomized controlled trial of postmenopausal women who received either a placebo or ginseng for 16 weeks revealed the superiority of ginseng on measures of psychological well-being. (29) Another double-blind randomized controlled trial, however, failed to find an effect of ginseng on positive affect, negative affect, or total mood disturbance in 83 healthy adults who took the herb for 8 weeks. (30) Thus, at best, SOR=B for the evidence in support of ginseng, but only at best in relation to psychological well-being.

Mechanisms of action. The key active components of Panax ginseng are ginsenosides, a group of steroidal saponins that target a multitude of tissues to produce pharmacologic responses. The overall pharmacology of ginseng is complex due to the ability of ginsenosides to initiate multiple actions in the same tissue. Attele and colleagues (31) provide an in-depth review of these mechanisms.

Herb-drug interactions. Ginseng may potentiate the effect of MAO inhibitors, (32) stimulants (including caffeine), and haloperidol. (33) In addition, a case study suggests a probable interaction with warfarin. (34)

Adverse effects. Reported side effects include insomnia, hypertension, diarrhea, restlessness, anxiety, and euphoria. (35) There is at least 1 report of ginseng-induced mania, which occurred within 4 to 10 days of a patient's interrupting a lithium and amitriptyline treatment. (26)

Evening primrose

Evening primrose (Oenothera biennis L) is a plant native to North America. The oil pressed from its seed is marketed as a nutritional supplement, and it has been used to treat many disorders, including premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD), both which are marked by affective disturbances. (36,37)

Efficacy. A systematic review (38) of the efficacy of evening primrose oil in the treatment of PMS revealed few clinical trials of adequate methodology. The authors found only 2 well-controlled studies, both which failed to show beneficial effects for the herb. Thus, at best, SOR=C for the evidence in support of evening primrose.

Mechanisms of action. Gamma linolenic acid, a precursor of prostaglandin E and several other active substances, is the main constituent responsible for the therapeutic effects of evening primrose. (37)

Herb-drug interactions. This herb has the potential to interact with phenothiazines, nonsteroidal anti-inflammatory drugs, corticosteroids, beta-blockers, and anticoagulants. (9)

Adverse effects. Although it is generally safe, evening primrose oil has occasionally exacerbated the symptoms of epilepsy.39 Other adverse effects are nausea, softening of the stool, and headache. (37)


Ephedra (Ephedra sinica) is an evergreen shrub native to Asia used in traditional Chinese medicine for thousands of years. In recent decades, ma-huang, the extract derived from this herb, has been a common ingredient in many natural supplements that promote increased energy, mood enhancement, and weight loss. (40,41) In early 2004, the FDA banned the sale of dietary products containing ephedra due to concerns over its adverse effects. (42)

Efficacy. Research on ephedra's efficacy is largely focused on its role in weight loss, and there is little evidence that evaluates it as a mood enhancer. A comprehensive meta-analysis (43) assessed 20 controlled trials with a treatment duration of at least 8 weeks and concluded that ephedra, when administered alone or with caffeine, promotes modest short-term weight loss (0.9 kg/month more than placebo). However, not all of the included studies were randomized or double-blind, and no data were available on long-term effects. A smaller systematic review (44) of 5 double-blind studies also found the combination of ephedra and caffeine stimulated weight loss, but it was unclear whether 2 of the trials were randomized. Thus, SOR=A for the evidence in support of weight loss in the short term. There is no evidence in support of it as a mood-enhancing treatment.

Mechanisms of action. The primary constituents of ephedra are ephedrine-type alkaloids. As a sympathomimetic agonist at both [alpha]- and [beta]-adrenergic receptors, ephedrine enhances cardiac rate and contractibility, peripheral vasoconstriction, bronchodilation, and central nervous system stimulation. (41)

Herb-drug interactions. Ephedra should not be used with anesthetic agents, (45) MAO inhibitors, (46,47) antihypertensives, or antidepressants. (41)

Adverse effects. The relative risk of adverse reactions to ephedra is more than 100 times greater than that of all other herbs. (40) As noted by Jacobs and Hirsch, (48) between 1993 and 1997 the FDA had received 34 notices of death and reports of approximately 800 medical and psychiatric complications all directly linked to ephedra. A more recent review (49) indicated that hypertension, palpitations, tachycardia, stroke, seizures, and death are related to ephedra use. The herb has also been noted to induce symptoms of psychosis and affective disturbances. (50,51)

* Anxiety


Kava-kava is derived from the dried rhizome of the oceanic kava plant (Piper methysticum), and it has been cultivated for thousands of years throughout the South Pacific, where it is consumed as a psychotropic drink for recreational and medicinal purposes. (52) Kava has been shown to alleviate anxiety symptoms, (53) and it has euphoric and muscle relaxant properties, although its effect on arousal and alertness appears to be minimal. (9) It is commonly used in Europe and North America for its anxiolytic effects.

Efficacy. A Cochrane review (54) of 6 double-blind randomized controlled trials that used a common outcome measure (Hamilton Anxiety Scale) concluded that kava is significantly superior to placebo as a short-term treatment for anxiety. The authors note, however, that further investigation is required to determine long-term efficacy and safety. Another meta-analysis (55) of 7 double-blind randomized controlled trials also suggests that, relative to a placebo, kava is an efficacious treatment for anxiety. Thus, SOR=A for the evidence in support of short-term efficacy in kava in anxiety. However, long-term data in terms of safety and efficacy has not been shown.

Mechanisms of action. Kavapyrones are the major constituents of this herb and are responsible for its pharmacologic activity. The mechanisms of their anxiolytic effect are still unclear. One line of research suggests that kavapyrones might mediate sedative effects by influencing gamma-aminobutyric acid (GABA)(A) receptor binding, (56-58) whereas another theory posits that kavapyrones are a reversible inhibitor of human platelet MAO-B. (52) Others have suggested the inhibition of voltage-gated ion channels as a potential mechanism of action. (59,60)

Herb-drug interactions. This herb has the potential to interact with benzodiazepines, (61) and the combination with central nervous system depressants like ethanol and barbiturates can produce synergistic effects. (56,62)

Adverse effects. Liver damage has been reported in patients who use kava. (63-65) A recent study (66) analyzed 29 cases of purported liver dysfunction in addition to 7 cases that have already been published; the authors concluded that kava ingestion was the direct cause of liver injury in 3 cases, a probable cause in 21 cases, and a possible cause in 12 cases. The most frequent liver injury was necrosis. Other adverse effects of this herb include dizziness, mild gastrointestinal disturbance, and a temporary yellow discoloration of skin, hair, and nails. (67) In addition, long-term administration of kava at higher doses my cause scaling of the skin on the extremities, also known as kava dermopathy. (68)


Valerian (Valerian officinalis) is a root extract, with purported healing properties that can be traced to ancient Greece and Rome. Today, valerian root preparations are used for their sedative, anxiolytic, and antidepressant properties. The herb, a GABA agonist, (9) is commonly used in the treatment of sleeplessness and the management of anxiety associated with muscle tension. (10)

Efficacy. A recent systematic review of randomized clinical trials (including reports in all languages) assessed the efficacy of valerian in patients with insomnia. (69) Nine randomized, double-blind, placebo-controlled trials satisfied the inclusion criteria; however, even in these studies questionable methods in randomization, blinding, compliance, withdrawal, confounding variables, diagnostic criteria, and statistical analysis rendered contradictory results, and the authors concluded that evidence for valerian in the treatment of insomnia is inconclusive.

Data to confirm valerian's effectiveness as an anxiolytic are also minimal. One randomized placebo-controlled pilot study examined the effects of valerian on generalized anxiety disorder; 36 patients were treated with placebo, diazepam, or valerian extract for 4 weeks. (70) The authors found a significant reduction in the psychic factors of anxiety with diazepam and valerian. However, the study was limited by the small number of patients in each group, relatively low dosages of the active agents, and a short duration of treatment. Similar studies (71) suffer from the same shortcomings, and thus further research is necessary to assess the effect of valerian on anxiety. Thus, SOR=C for the evidence in support of valerian as a somnolent and as a anxiolytic, and further research is necessary to assess the effect of valerian in insomnia and anxiety

Mechanisms of action. Valerian's constituents include sesquiterpenes of the volatile oil (including valeric acid), iridoids (valepotriates), alkaloids, furanofuran lignans, and free amino acids such as GABA, tyrosine, arginine, and glutamine. (72) The precise mechanisms of action are still unclear, though it has been suggested that all of the active constituents act synergistically to produce a clinical response. Research has also demonstrated modulation of GABA neurotransmission and receptor function (see Houghton (73) for a comprehensive review of valerian's pharmacology).

Herb-drug interactions. Valerian has the potential to prolong thio-, pental-, and pentobarbital-induced sleep and should, therefore, not be combined with barbiturates. (74,75) It may also potentiate the sedative effects of anesthetics and other central nervous system depressants. (45)

Adverse effects. Adverse affects with this product are rare, but when they occur they may include headaches, excitability, uneasiness, gastrointestinal effects, dizziness, and cardiac disturbances. (76-78)

* Dementia


Ginkgo extracts are derived from one of the oldest known tree species (Ginkgo biloba L). They have been used in traditional Chinese medicine for 5000 years for a variety of purposes and are believed to be helpful in the treatment of memory impairment caused by dementia. (79) The herb is also used to treat stress, fatigue, chronic cerebrovascular insufficiency, and cerebral trauma, and to improve endurance. (9)

Efficacy. Evidence for ginkgo's efficacy is encouraging, but more rigorous research is needed. Kleijnen and Knipschild (80) reviewed 40 controlled trials on the use of ginkgo to treat "chronic cerebral insufficiency." Only 8 of the studies were deemed to be of good quality, although all but 1 found clinically significant improvement in symptoms including memory loss, concentration difficulties, fatigue, anxiety, and depressed mood.

Another meta-analysis (79) identified more than 50 articles on the effect of ginkgo on the cognitive function in Alzheimer patients, but only 4 studies were found to be properly blinded and placebo-controlled with well-characterized subjects. The authors concluded that gingko appears to have a modest effect on cognitive function in Alzheimer's but note that further research is necessary.

A systematic review by Ernst and colleagues (81) concluded that ginkgo was superior to a placebo in delaying the clinical course of dementia. The authors reported on 9 placebo controlled, double-blind randomized trials including 1497 patients in their analysis.

Ginkgo has also been used to treat impotence, including antidepressant-induced sexual dysfunction. In 1 trial, 60 patients with proven arterial erectile dysfunction who had not previously responded to papaverine showed improvement with a daily dose of 60 mg of ginkgo over 12 to 18 months. (9) However, further research must be undertaken in this domain, in part because this trial was not blinded, with both doctors and patients aware of who was receiving the ginkgo treatment.

Thus, SOR=A for the evidence in support of ginkgo as a cognitive enhancer in mild to moderate dementia, and B for the evidence in support of ginkgo as a treatment for erectile dysfunction.

Mechanisms of action. Ginkgo leaves contain several bioactive compounds, including flavonoids, terpenoids (ginkgolide, bilbobide), and organic acids. Although the mechanisms of action are only partially understood, the main effects appear to be related to its antioxidant properties, which require the synergistic action of the principal constituents. (82) These compounds act as free radical scavengers. (83) Other pharmacologic actions involve antihypoxic and antiplatelet effects. (84)

Herb-drug interactions. Researchers have suggested that ginkgo may potentiate other anticoagulants or increase bleeding over time, (85,86) which can be attributed to ginkgolide B, a potent inhibitor of platelet-activating factor needed for inducing arachidonate-independent platelet aggregation. (87) Caution should be exercised when ginkgo is taken in conjunction with anticoagulant treatment (including aspirin) or when there is a risk of bleeding (eg, peptic ulcer disease and subdural hematoma). (9,86)

Adverse effects. Side effects from ginkgo appear to be relatively uncommon; however, they may include headaches, gastrointestinal tract upset, nausea, vomiting, and a skin allergy to the ginkgo fruit. (17,88)

* Sexual dysfunction


Yohimbine is an alkaloid derived from the cortex of the Central African tree Corianthe yohimbe. (89) The bark of the tree was used traditionally to enhance virility. Today, yohimbine is still reputed as an aphrodisiac and used as a remedy for erectile problems. (90)

Efficacy. Overall, the efficacy of yohimbine in the treatment of erectile dysfunction appears promising, although, as with studies of other herbal products, clinical trials often suffer from methodological flaws. Carey and Johnson (91) conducted 4 independent meta-analyses to examine the effects of yohimbine alone or in combination with other drugs in controlled and uncontrolled trials. The authors found positive results for yohimbine across all 4 analyses, but they note that the highest-quality data were derived from controlled clinical trials when yohimbine was administered on its own. In their analysis, this included 242 patients across 4 studies. Another systematic review yielded similar results: a meta-analysis of 7 randomized, placebo-controlled trials including 419 patients demonstrated that yohimbine is superior to placebo as a treatment for erectile dysfunction. (89) Thus, SOR=A for the evidence in support of yohimbine as a treatment for erectile dysfunction.

Mechanisms of action. Yohimbine is an [alpha.sub.2]-adrenergic antagonist. Its blocking activity increases the release of noradrenaline and the firing rate of noradrenergic neurons in the central nervous system. (92)

Herb-drug interactions. Yohimbine should not be taken with sibutramine, a serotonin and norepinephrine reuptake inhibitor. The concomitant use of the 2 products could unmask the peripheral effect of sibutramine and produce negative cardiovascular effects. (93) Potential interactions also exist with heart or blood pressure medications, (94) lithium (95) morphine, (96) and alcohol. (97)

Adverse effects. Adverse effects are not common with yohimbine; however, they may include headaches, sweating, agitation, hypertension, and restlessness. (98) Yohimbine has also been reported to contribute to psychotic symptoms, mania, and seizures, though such occurrences are not well documented. (9)

* Growing need for the 2 worlds to merge

One of the most frequent scenarios encountered by the naturopath is the patient who is taking a psychotropic medication and wants to explore natural solutions to reduce the drug's unpleasant side effects or to enhance general well being. Sharing information is the key to a healthy treatment regimen for such individuals (TABLES 3 AND 4). The patient should inform both the physician and naturopath about health care decisions, the naturopath must encourage the patient to be candid with the physician about proposed treatments, and the physician can be helpful by communicating to the naturopath the extent of the patient's disorder.

Professionally, one must consider before asking a patient to discontinue one agent or the other whether the alternative treatment might be improving the patient's condition or reducing negative side effects caused by the psychotropic medication. On one hand, withdrawing the drug can destabilize the patient's condition, which may not be rapidly amenable to a botanical or nutritional treatment. Alternatively, to supplement an antidepressant, benzodiazepine, or antipsychotic regimen by adding an herbal preparation could lead to unpredictable interactions and unpleasant or even dangerous symptoms. For many cases of mild depression or mild anxiety disorder, natural therapies can be sufficient treatment. However, for more complicated cases, where little is known about the consequences of using alternative treatments, involvement by a clinician with more specialized training is recommended.


(1.) Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States--prevalence, costs and patterns of use. N Engl J Med 1993; 328:246-252.

(2.) Eisenberg DM, Davis RB, Ettner SL, et al. Trends in Alternative Medicine Use in the United States, 1990-1997: Results of a Follow-up National Survey. JAMA 1998; 280:1569-1575.

(3.) Pies R. Adverse neuropsychiatric reactions to herbal and over-the counter "antidepressants." J Clin Psychiatry 2000; 61:815-820.

(4.) Knaudt PR, Connor KM, Weisler RH, Churchill LE, Davidson JRT. Alternative therapy use by psychiatric outpatients. J Nerv Ment Dis 1999; 187:692-695.

(5.) Mamtani R, Cimino A. A primer of complementary and alternative medicine and its relevance in the treatment of mental health problems. Psychiatr Quart 2002; 73:367-381.

(6.) Wharton R, Lewith G. Complementary medicine and the general practitioner. BMJ 1986; 292:1498-1500.

(7.) Scimone A, Scimone AA. Recommendation of herbal remedies by psychiatrists. J Orthomol Med 2001; 16:155-156.

(8.) Wong AHC, Smith M, Boon HS. Botanical medicine in psychiatry. Psychiatry Rounds 1999; 3(2):1-5.

(9.) Wong AHC, Smith M, Boon HS. Herbal remedies in psychiatric practice. Arch Gen Psychiatry 1998; 55:1033-1044.

(10.) Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression: An overview and meta-analysis of randomized clinical trials. BMJ 1996; 313:253-258.

(11.) Linde K, Mulrow CD. St. John's wort for depression (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chinchester, UK: John Wiley & Sons, Ltd.

(12.) Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression. JAMA 2001; 285:1978-1986.

(13.) Davidson JRT. Effect of Hypericum perforatum (St John's wort) in major depressive disorder. JAMA 2002; 287:1807-1814.

(14.) Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004; 11:98-104.

(15.) Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35:35-98.

(16.) Ernst E. Second thoughts about safety of St John's wort. Lancet 1999; 354:2014-2016.

(17.) Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002; 136:42-53.

(18.) Hall S, Wang Z, Huang S, et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74:525-535.

(19.) Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000; 355:547-548.

(20.) Gordon JB. SSRIs and St. John's wort: Possible toxicity? Am Fam Physician 1998; 57:950-953.

(21.) Johne A, Brockmoller J, Bauer S. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66:338-345.

(22.) Walter G, Rey JM, Harding M. Psychiatrists" experience and views regarding St. John's wort and 'alternative' treatments. Aust NZ J Psychiatry 2000; 34:992-996.

(23.) Newall C, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1996.

(24.) O'Breasail AM, Argouarch S. Hypomania and St. John's wort. Can J Psychiatry 1998; 43:747.

(25.) Moses EL, Mallinger AG. St. John's wort: Three cases of possible mania induction. J Clin Psychopharmacol 2000; 20:115-117.

(26.) Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: Report of a possible case. J Clin Psychopharmacol 1995; 15:447-448.

(27.) Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol 1999; 55:567-575.

(28.) Kieffer D, Pantuso T. Panax ginseng. Am Fam Physician 2003; 68:1539-1542.

(29.) Wiklund IK, Mattsson LA, Lindgren R, Limoni C. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group. Int J Clin Pharmacol Res 1999; 19:89-99.

(30.) Cardinal BJ, Engels HJ. Ginseng does not enhance psychological well-being in healthy, young adults: results of a double-blind, placebo-controlled, randomized clinical trial. J Am Diet Assoc 2001; 101:656-660.

(31.) Attele AS, Wua JA, Yuan CS. Ginseng pharmacology: Multiple constituents and multiple actions. Biochem Pharmacol 1999; 58:1685-1693.

(32.) Stockley I. Drug Interactions: A Sourcebook of Adverse Interactions, Their Mechanisms, Clinical Importance, and Management. 3rd ed. Cambridge, England: Blackwell Scientific Press; 1994.

(33.) Mitra SK, Chakraborti A, Bhattacharya SK. Neuropharmacological studies on Panax ginseng. Indian J Exp Biol 1996; 34:41-47.

(34.) Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997; 54:692-693.

(35.) Siegel RK. Ginseng abuse syndrome. JAMA 1979; 241:1614-1615.

(36.) Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol 2003; 188(5 Suppl):S56-S65.

(37.) Kleijnen J. Evening primrose oil. BMJ 1994; 309:824-825.

(38.) Budeiri D, Li Wan Po A, Dornan JC. Is evening primrose oil of value in the treatment of premenstrual syndrome? Controlled Clinical Trials 1996; 17:60-68.

(39.) Barber HJ. Evening primrose oil: A panacea? Pharm J 1988; 240:723-725.

(40.) Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 138:468-471.

(41.) Abourashed EA, El-Alfy AT, Khan IA, Walker L. Ephedra in perspective--a current review. Phytother Res 2003; 17:703-712.

(42.) Rados C. Ephedra ban: no shortage of reasons. FDA Consum 2004; 38:6-7.

(43.) Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289:1537-1545.

(44.) Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev 2001; 2:199-211.

(45.) Ang-Lee M, Moss J, Yuan C. Herbal medicines and perioperative care. JAMA 2001; 286:208-216.

(46.) Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med 1995; 12:49-51.

(47.) Brinker F. Interactions of pharmaceutical and botanical medicines. J Naturopathic Med 1997; 7:14-20.

(48.) Jacobs KM, Hirsch KA. Psychiatric complications of ma-huang. Psychosomatics 2000; 41:58-62.

(49.) Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343:833-838.

(50.) Doyle H, Kargin M. Herbal stimulant containing ephedrine has also caused psychosis. BMJ 1996; 313:756.

(51.) Capwell RR. Ephedrine-induced mania from an herbal diet supplement. Am J Psychiatry 1995; 152:647.

(52.) Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from piper methysticum forster (kava-kava). Pharmacopsychiat 1998; 31:187-192.

(53.) Volz HP, Kieser M. Kava-kava extract WS 1490 verses placebo in anxiety disorders: A randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiat 1997; 30:1-5.

(54.) Pittler MH, Ehret V. Kava extract for treating anxiety (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.

(55.) Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 2000; 20:84-90.

(56.) Jussofie A, Schmiz A, Himke C. Kava-pyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Bed) 1994; 116:469-474.

(57.) Boonen G, Haberlein H. Influence of genuine kavapyrone enantiomers on the GABAA binding site. Planta Med 1998; 64:504-506.

(58.) Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DD. Kava pyrones and resin: studies on GABA-A, GABA-B, and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 1992; 712:120-126.

(56.) Gleitz J, Belle A, Peters T. ([+ or -])-Kavain inhibits veratridine-activated voltage- dependent Na+-channels in synaptosomes prepared from rat cerebral cortex. Neuropharmacology 1995; 34:1133-1138.

(60.) Magura El, Kopanitsa MV, Gleitz J, Peters T, Krishtal OA. Kava extract ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage-operated Na+-channels in rat CA1 hippocampal neurons. Neuroscience 1997; 91:346-351.

(61.) Almeida JC, Grimsley EW. Coma from the health food store: Interaction between kava kava and alprazolam. Annu Int Med 1996; 125:940-941.

(62.) Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev 1997; 16:147-155.

(63.) Kraft M, Spahn TW, Menzel J, et al. Fulminant liver failure after administration of the herbal antidepressant kava-kava. Dtsch Med Wochenschr 2001; 126:970-972.

(64.) Strahl S, Ehret V, Dahm HH, Maier KP. Necrotizing hepatitis after taking herbal remedies. Dtsch Med Wochenschr 1998; 23:1410-1414.

(65.) Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with kava, a herbal remedy for anxiety. BMJ 2001; 322:7279.

(66.) Stickel F, Baumuller HM, Seitz K, et al. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003; 39:62-67.

(67.) Blumenthal M, Busse W, Goldberg A, et al, eds. The Complete German Commission E Monographs-Therapeutic Guide to Herbal Medicines. Austin: American Botanical Council; Boston: Integrative Medicine Communications; 1998.

(68.) Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 31:89-97.

(69.) Stevinson C, Ernst E. Valerian for insomnia: A systematic review of randomized clinical trials. Sleep Medicine 2000; 1:91-99.

(70.) Andreatini R, Sartori V, Seabra M, Leite J. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002; 16:650-654.

(71.) Cropley M, Cave Z, Ellis J, Middleton R. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res 2002; 16:23-27.

(72.) Hadley S, Petry J. Valerian. Am Fam Physician 2003; 67:1755-1758.

(73.) Houghton P. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999; 51:505-512.

(74.) Hiller K, Zetler G. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L: Behavioural and anticonvulsant properties. Physiother Res Int 1996; 10:145-151.

(75.) Capasso A, DeFeo V, DeSimon F, Sorrentino L. Pharmacological effects of aqueous extracts from Valeriana adscendens. Physiother Res Int 1996; 10:309-312.

(76.) McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, Fla: CRC Press; 1997.

(77.) Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 2000; 33:47-53.

(78.) Kuhlmann J, Berger W, Podzuweit H, Schmidt U. The influence of valerian treatment on "reaction time, alertness and concentration" in volunteers. Pharmacopsychiatry 1999; 32:235-241.

(79.) Oken B, Storzbach D, Kaye J. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55:1409-1415.

(80.) Kleijnen J, Knipschild R Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992; 34:352-358.

(81.) Ernst E, Pittler M. Ginkgo biloba for dementia: a systematic review of double-blind, placebo-controlled trials. Clin Drug Invest 1999; 17:301-308.

(82.) Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997; 278:1327-1332.

(83.) Oyama Y, Fuchs P, Katayama N, Noda K. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-Ioaded brain neurons. Brain Res 1994; 635:125-129.

(84.) Cupp M, ed. Toxicology and Clinical Pharmacology of Herbal Products. Totowa, NJ: Humana Press; 2000.

(85.) Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo. Neurol 1996; 46:1775-1776.

(86.) Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997; 336:1108.

(87.) Miller LG. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158:2200-2211.

(88.) Houghton P. Ginkgo. Pharm J 1994; 253:121-122.

(89.) Ernst E, Pittler M. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159:433-436.

(90.) Morales A. Yohimbine in erectile dysfunction: The facts. Int J Impot Res 2000; Suppl 1:S70-S74.

(91.) Carey M, Johnson B. Effectiveness of yohimbine in the treatment of erectile disorder: Four meta-analytic integrations. Arch Sex Behav 1996; 25:341-360.

(92.) Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: Biochemical and behavioural correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987; 144:1030-1036.

(93.) Jordan J, Sharma A. Potential for sibutramine-yohimbine interaction? Lancet 2003;361:1826.

(94.) Goldstein D, Grossman E, Listwak S, Folio C. Sympathetic reactivity during a yohimbine challenge test in essential hypertension. Hypertension 1991; 18 (Suppl 3):40-48.

(95.) Price L, Charney D, Heninger G. Three cases of manic symptoms following yohimbine administration. Am J Psychiatry 1984; 141:1267-1268.

(96.) Gear R, Gordon N, Heller P, Levine J. Enhancement of morphine analgesia by the alpha2-adrenergic antagonist yohimbine. Neuroscience 1995; 66:5-8.

(97.) McDougle C, Krystal J, Price L, Heninger G, Charney D. Noradrenergic response to acute ethanol administration in healthy subjects: comparison with intravenous yohimbine. Psychopharmacology (Berl) 1995; 118:127-135.

(98.) Rowland D, Tai W. A review of plant-derived and herbal approaches to the treatment of sexual dysfunctions. J Sex Marital Ther 2003; 29:185-205.

(99.) Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70:317-326.

(100.) Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kava lactones. Drug Metab Dispos 2002; 30:1153-1157.

(101.) Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 2001; 92:147-163.

(102.) Gardener D. Evidence-based decisions about herbal products for treating mental disorders. J Psychiatry Neurosci 2002; 27:324-333.

Deficiencies to overcome

Because many alternative options do not require the approval of the US Food and Drug Administration (FDA), products sold in health food stores can be purchased without a prescription or the provision of any clinical advice or professional review. The quality of many herbal preparations is thus unpredictable, with the content varying not only from brand to brand but also from batch to batch. (5)

A working knowledge of the pharmacologic data and clinical literature is necessary to properly counsel, diagnose, and treat patients who may be using herbal products. However, 1 study reported that only 5% of British doctors claimed more than a poor knowledge of herbal medicine, (6) and another survey revealed that most psychiatrists who do not recommend herbal products avoid doing so because they feel uncomfortable with their current knowledge of alternative therapies. (7) Alarmingly, the latter study reported that among psychiatrists who do not recommend herbal treatments, the safety of such treatments is not an issue in their decision-making process.

Methods used for this review

Literature searches were conducted using Medline, PsycInfo, and the Cochrane Library electronic databases, and by consulting bibliographies of pertinent publications. We focused primarily on meta-analyses and large-scale case report tabulations at an evidence level of 1b. Additionally, articles selected included those that discussed the use of herbal treatments for mental illness, as well as those that addressed drug-herb interactions between herbal and traditional psychiatric drug treatments.

Monica Vermani, Hon.BSc, MA

Stress, Trauma, Anxiety, Rehabilitation Treatment (S.T.A.R.T.) Clinic for Mood & Anxiety Disorders, Toronto, Canada; Adler School of Professional Psychology, Chicago, III

Irena Milosevic, Hon.BSc University of Toronto, Toronto, Canada

Fraser Smith, BA, ND Canadian College of Naturopathic Medicine, Toronto, Canada

Martin A. Katzman, SSc, MD, FRCPC

Stress, Trauma, Anxiety, Rehabilitation Treatment (S.T.A.R.T.) Clinic for Mood & Anxiety Disorders, Toronto, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto


Martin A. Katzman, BSc, MD, FRCPC, Stress, Trauma, Anxiety, Rehabilitation Treatment (S.T.A.R.T.) Clinic for Mood & Anxiety Disorders, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8. E-mail:

COPYRIGHT 2005 Dowden Health Media, Inc.
COPYRIGHT 2005 Gale Group

Return to Fraser syndrome
Home Contact Resources Exchange Links ebay